摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(3-{7-[3-(4-bromophenyl)-3-oxopropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}propyl)amino]benzonitrile | 335620-07-0

中文名称
——
中文别名
——
英文名称
4-[(3-{7-[3-(4-bromophenyl)-3-oxopropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}propyl)amino]benzonitrile
英文别名
4-[3-[7-[3-(4-Bromophenyl)-3-oxopropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl]propylamino]benzonitrile
4-[(3-{7-[3-(4-bromophenyl)-3-oxopropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}propyl)amino]benzonitrile化学式
CAS
335620-07-0
化学式
C25H29BrN4O2
mdl
——
分子量
497.435
InChiKey
LNXROAAVVLCEKW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    32
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    68.6
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2003101956A1
    公开(公告)日:2003-12-11
    There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.
    提供了一种组合产品,包括:(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物(或其衍生物)或药用可接受的衍生物;以及(1)WO 01/28992中权利要求1定义的化合物或(2)WO 01/28992中权利要求34的化合物或(3)化合物A或B或C或D(或药用可接受的盐)用于治疗心律不齐或其凝血控制的并发症。
  • New oxabispidine compounds useful in the treatment of cardiac arrhythmias
    申请人:Bjore Annika
    公开号:US20060166979A1
    公开(公告)日:2006-07-27
    There is provided compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 41 to R 46 , A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了公式I的化合物,其中R1、R2、R3、R4、R41到R46、A、B和G在描述中给出了它们的含义,这些化合物在预防和治疗心律失常方面有用,特别是房性和室性心律失常。
  • Pharmaceutical combination
    申请人:Roth-Rosendahl Ann-Charlotte
    公开号:US20060052314A1
    公开(公告)日:2006-03-09
    There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivateive thereof) or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 or WO 01/28993 or (2) compound of claim 34 or WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts therof) for use in treating arrhythmia or a coagulation controlled complicaiton thereof.
    提供了一种组合产品,包括:(1)WO 02/44145中权利要求1的化合物或权利要求20的化合物(或其衍生物)或其药学上可接受的衍生物;和(2)权利要求1或WO 01/28993中定义的化合物或(3)权利要求34或WO 01/28992中的化合物A或B或C或D(或其药学上可接受的盐),用于治疗心律失常或其凝血控制并发症。
  • Oxabispidine compounds useful in the treatment of cardiac arrhythmias
    申请人:Bjore Annika
    公开号:US20070117799A1
    公开(公告)日:2007-05-24
    There is provided compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 41 to R 46 , A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了式I的化合物,其中R1、R2、R3、R4、R41至R46、A、B和G的含义在说明中给出,这些化合物在预防和治疗心律失常,特别是心房和心室心律失常方面是有用的。
  • New oxabispidine compunds useful in the treatment of cardiac arrhythmias
    申请人:Bjore Annika
    公开号:US20090326221A1
    公开(公告)日:2009-12-31
    There is provided compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 41 to R 46 , A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    提供了I式化合物,其中R1、R2、R3、R4、R41至R46、A、B和G具有描述中给出的含义,这些化合物在预防和治疗心律失常,特别是房颤和室性心律失常方面具有用途。
查看更多